CoChat

Selective inhibitors of SARM1 targeting an allosteric cysteine in the autoregulatory ARM domain

Open access
Feldman, Hannah C., Merlini, Elisa, Guijas, Carlos, DeMeester, Kristen E., Njomen, Evert, Kozina, Ellen M., Yokoyama, Minoru, Vinogradova, Ekaterina, Reardon, Holly T., Melillo, Bruno, Schreiber, Stuart L., Loreto, Andrea, Blankman, Jacqueline L., Cravatt, Benjamin F. · 2022 · Proceedings of the National Academy of Sciences
Cited by 75

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

The nicotinamide adenine dinucleotide hydrolase (NADase) sterile alpha toll/interleukin receptor motif containing-1 (SARM1) acts as a central executioner of programmed axon death and is a possible therapeutic target for neurodegenerative disorders. While orthosteric inhibitors of SARM1 have been described, this multidomain enzyme is also subject to intricate forms of autoregulation, suggesting the potential for allosteric modes of inhibition. Previous studies have identified multiple cysteine residues that support SARM1 activation and catalysis, but which of these cysteines, if any, might be selectively targetable by electrophilic small molecules remains unknown. Here, we describe the chemical proteomic discovery of a series of tryptoline acrylamides that site-specifically and stereoselectively modify cysteine-311 (C311) in the noncatalytic, autoregulatory armadillo repeat (ARM) domain of SARM1. These covalent compounds inhibit the NADase activity of WT-SARM1, but not C311A or C311S SARM1 mutants, show a high degree of proteome-wide selectivity for SARM1_C311 and stereoselectively block vincristine- and vacor-induced neurite degeneration in primary rodent dorsal root ganglion neurons. Our findings describe selective, covalent inhibitors of SARM1 targeting an allosteric cysteine, pointing to a potentially attractive therapeutic strategy for axon degeneration-dependent forms of neurological disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2208457119

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 75

Metadata

Authors
Feldman, H. C., Merlini, E., Guijas, C., DeMeester, K. E., Njomen, E., Kozina, E. M., Yokoyama, M., Vinogradova, E., Reardon, H. T., Melillo, B., Schreiber, S. L., Loreto, A., Blankman, J. L., & Cravatt, B. F.
Venue
Proceedings of the National Academy of Sciences
Published
2022-08-22
Volume
119
Issue
35
Pages
e2208457119-e2208457119
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W4292651687
Cited by
75
References
12
FWCI
4.14
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective inhibitors of SARM1 targeting an allosteric cysteine in the autoregulatory ARM domain. https://app.cochat.ai/papers/10.1073/pnas.2208457119
The paper
Feldman, H. C., Merlini, E., Guijas, C., DeMeester, K. E., Njomen, E., Kozina, E. M., Yokoyama, M., Vinogradova, E., Reardon, H. T., Melillo, B., Schreiber, S. L., Loreto, A., Blankman, J. L., & Cravatt, B. F. (2022). Selective inhibitors of SARM1 targeting an allosteric cysteine in the autoregulatory ARM domain. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2208457119

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.